Serina Therapeutics Stock Buy Hold or Sell Recommendation
| SER Stock | 2.66 0.22 9.02% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Serina Therapeutics is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated analysis based on historical performance and your stated risk tolerance. It serves as guidance on whether to purchase or sell Serina Therapeutics within the specified time frame.Check out Serina Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide. Note, we conduct extensive research on individual companies such as Serina and provide practical buy, sell, or hold advice based on investors' constraints. Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Execute Serina Therapeutics Buy or Sell Advice
The Serina recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Serina Therapeutics. Macroaxis does not own or have any residual interests in Serina Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Serina Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weakest | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Serina Therapeutics Trading Alerts and Improvement Suggestions
| Serina Therapeutics generated a negative expected return over the last 90 days | |
| Serina Therapeutics has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 56 K. Reported Net Loss for the year was (11.21 M) with loss before taxes, overhead, and interest of (12 M). | |
| Serina Therapeutics has about 3.67 M in cash with (17.14 M) of positive cash flow from operations. | |
| Serina Therapeutics has a very weak financial position based on the latest SEC disclosures | |
| Roughly 47.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Moreadith of Serina Therapeutics sells shares worth 15,167 - Investing.com |
Serina Therapeutics Returns Distribution Density
The distribution of Serina Therapeutics' historical returns is an attempt to chart the uncertainty of Serina Therapeutics' future price movements. The chart of the probability distribution of Serina Therapeutics daily returns describes the distribution of returns around its average expected value. We use Serina Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Serina Therapeutics returns is essential to provide solid investment advice for Serina Therapeutics.
| Mean Return | -1 | Value At Risk | -7.48 | Potential Upside | 5.51 | Standard Deviation | 4.09 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Serina Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Serina Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (1.8M) | (350.2K) | 217.4K | 7.1M | (3.9M) | (3.7M) | |
| Free Cash Flow | (7.8M) | (2.4M) | (2.1M) | (3.0M) | (17.2M) | (16.3M) | |
| Depreciation | 1.3M | 33.4K | 61.3K | 90K | 194K | 184.3K | |
| Other Non Cash Items | 1.6M | (347.6K) | 550.0K | (7.9M) | (5.4M) | (5.1M) | |
| Capital Expenditures | 20K | 108.4K | 9.7K | 504K | 22K | 20.9K | |
| Net Income | (10.4M) | (1.3M) | (2.7M) | 5.3M | (11.2M) | (11.8M) | |
| End Period Cash Flow | 527K | 314.8K | 532.2K | 7.6M | 3.7M | 2.6M |
Serina Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Serina Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Serina Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Serina stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.1 | |
β | Beta against Dow Jones | 1.25 | |
σ | Overall volatility | 4.37 | |
Ir | Information ratio | -0.26 |
Serina Therapeutics Volatility Alert
Serina Therapeutics exhibits very low volatility with skewness of 0.18 and kurtosis of 0.01. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Serina Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Serina Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Serina Therapeutics Fundamentals Vs Peers
Comparing Serina Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Serina Therapeutics' direct or indirect competition across all of the common fundamentals between Serina Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Serina Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Serina Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Serina Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Serina Therapeutics to competition |
| Fundamentals | Serina Therapeutics | Peer Average |
| Return On Equity | -4.85 | -0.31 |
| Return On Asset | -1.38 | -0.14 |
| Operating Margin | (188.69) % | (5.51) % |
| Current Valuation | 23.66 M | 16.62 B |
| Shares Outstanding | 10.66 M | 571.82 M |
| Shares Owned By Insiders | 47.29 % | 10.09 % |
| Shares Owned By Institutions | 4.35 % | 39.21 % |
| Number Of Shares Shorted | 36.4 K | 4.71 M |
| Price To Book | 29.88 X | 9.51 X |
| Price To Sales | 224.31 X | 11.42 X |
| Revenue | 56 K | 9.43 B |
| Gross Profit | (12 M) | 27.38 B |
| EBITDA | (10.49 M) | 3.9 B |
| Net Income | (11.21 M) | 570.98 M |
| Cash And Equivalents | 3.67 M | 2.7 B |
| Total Debt | 268 K | 5.32 B |
| Book Value Per Share | (0.30) X | 1.93 K |
| Cash Flow From Operations | (17.14 M) | 971.22 M |
| Short Ratio | 2.48 X | 4.00 X |
| Earnings Per Share | (1.87) X | 3.12 X |
| Target Price | 13.0 | |
| Number Of Employees | 12 | 18.84 K |
| Market Capitalization | 26.02 M | 19.03 B |
| Total Asset | 6.72 M | 29.47 B |
| Retained Earnings | (44.32 M) | 9.33 B |
| Working Capital | 3.31 M | 1.48 B |
| Net Asset | 6.72 M |
Note: Disposition of 5673 shares by Moreadith Randall of Serina Therapeutics at 2.6737 subject to Rule 16b-3 [view details]
Serina Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Serina . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 1903.1 | |||
| Daily Balance Of Power | 0.7586 | |||
| Rate Of Daily Change | 1.09 | |||
| Day Median Price | 2.52 | |||
| Day Typical Price | 2.56 | |||
| Price Action Indicator | 0.26 | |||
| Period Momentum Indicator | 0.22 |
About Serina Therapeutics Buy or Sell Advice
When is the right time to buy or sell Serina Therapeutics? Buying financial instruments such as Serina Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Serina Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Driverless Cars Thematic Idea Now
Driverless Cars
It encompasses large technology companies, automotive makers, security firms, and thematic ETFs across multiple industries. These entities are directly or indirectly involved in shaping the development and marketing of self-driving vehicles. The Driverless Cars theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Driverless Cars Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.